Oncolytics Biotech Inc ONCY

New precision platform UK trial

[inthno]

There is a new precision platform trial initiated in the UK.

New phase 2 study launched to evaluate triple drug combination in pancreatic cancer

The PRIMUS-006 study will evaluate Lilly/Genentech’s Gemzar in combination with Merck’s Keytruda and Immodulon’s IMM-101

PRECISION-Panc is an ambitious programme of research that seeks to uncover the molecular profile of individual patients with pancreatic cancer, to learn more about the disease and to pave the way for patients entering clinical trials in a way that matches their tumour biology to the type of treatment

PRECISION-Panc

We’re investing £10 million to speed up our understanding of pancreatic cancer and work towards personalising treatment.

PRECISION-Panc is an ambitious programme of research that seeks to uncover the molecular profile of individual patients with pancreatic cancer, to learn more about the disease and to pave the way for patients entering clinical trials in a way that matches their tumour biology to the type of treatment.

At £10 million, it’s our biggest standalone investment in pancreatic cancer research to date and builds on our strategic focus on the disease.

https://www.cancerresearchuk.org/funding-for-researchers/applying-for-funding/how-to-make-a-successful-application/successful-applicant-case-studies/case-studies-of-major-research-programmes/precision-panc

 

[askretka]

UK is getting serious on ramping up some treatment opportunities for Pancreatic Cancer.  Over 70% of Pancreatic Cancer patients don't get a chance at treatment at the moment.